Back

Cost differences between oral anticoagulation therapies in atrial fibrillation patients

1 September 2024 (17:00 - 17:12)
Organised by: Logo
Congress Presentation Part of: Disparities: insights into socioeconomic factors and cardiovascular health Health Economics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Ossi Lehtonen

University of Eastern Finland, Kuopio (Finland)

4 More presentations in this session

Presentation thumbnail
Disparities by region, age, and sex in cardiovascular disease burden attributable to high fasting plasma glucose in China, 2010-2018: a nationwide, population-based study.
Miss X. Cao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Embedding a text message recall system to increase the uptake of cardiovascular screening in Australian general practice. Results of the Text to Detect randomised controlled trial
Miss N. Raffoul (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Independent associations of educational attainment and its joint associations with LE8 score for risk of cardiovascular disease incidence and mortality among Chinese people
Doctor Z. Chen (Changsha, CN)
Abstract Slides Video
Presentation thumbnail
Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States
Doctor S. Hennessy (Galway, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Disparities: insights into socioeconomic factors and cardiovascular health
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Temporal trends of ischemic stroke rates in atrial fibrillation without anticoagulation: a nationwide cohort study from 2007 to 2018
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
Temporal trends in initiation of oral anticoagulants and stroke-free survival among elderly and very elderly patients with new onset atrial fibrillation - a 20-year perspective.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources